#novo nordisk
Related Stories (12)
Novo Nordisk launches weekly insulin shot Awiqli in India - Reuters
Novo Nordisk launches weekly insulin shot Awiqli in India Reuters
July 9, 2026South African court grants Novo Nordisk petition to block Ozempic copies - Reuters
South African court grants Novo Nordisk petition to block Ozempic copies Reuters
June 22, 2026Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion - Reuters
Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion Reuters
June 16, 2026Novo Nordisk flags patient data breach from some clinical trials in cyberattack - Reuters
Novo Nordisk flags patient data breach from some clinical trials in cyberattack Reuters
June 11, 2026UK approves Novo weight-loss pill to edge open European market - Reuters
UK approves Novo weight-loss pill to edge open European market Reuters
June 11, 2026Weight-loss drug Wegovy to be available in pill form in UK for first time
Manufacturer Novo Nordisk says a daily tablet of the drug could be more convenient for some people than weekly injections.
June 11, 2026Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit - Reuters
Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit Reuters
March 9, 2026Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027 - Reuters
Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027 Reuters
February 24, 2026Novo Nordisk to halve US list price of Wegovy from 2027 - Reuters
Novo Nordisk to halve US list price of Wegovy from 2027 Reuters
February 24, 2026Stocks to watch as Trump's new tariffs spell more uncertainty - Reuters
Stocks to watch as Trump's new tariffs spell more uncertainty Reuters
February 23, 2026Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out - Reuters
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out Reuters
February 23, 2026Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial - Reuters
Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial Reuters
February 23, 2026Related Pages (19)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Hackare uppger dataintrång hos Novo – nobbades på lösensumma
Den kriminella hackergruppen Fulcrumsec hävdar att man har stulit över en terabyte data från den danska läkemedelsjätten Novo Nordisk. Det rapporterar Reuters. Gruppen hotar nu att sälja delar av mat
Novo Nordisk reveals cyberattack: Ozempic and Wegovy maker says clinical trials data breached
Fortunately the stolen data is pseudonymous When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Novo Nordisk, one of the biggest pharmaceutical com
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Wegovy weight-loss pills to be available for patients in UK to buy
Regulator approval means patients who meet criteria will be able to purchase tablets with private prescription Patients in the UK will soon be able to buy the Wegovy weight-loss pill, the medicines r
Novo Nordisk flags patient data breach from some clinical trials in cyberattack
Business FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. REUTERS/Tom Little/File Photo June 11 :
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Trump threatens ‘more powerful and obnoxious’ tariffs, amid confusion in UK and EU; Wall Street drops – as it happened
Confusion continues as to whether Donald Trump’s new 15% tariffs kick in tomorrow in the UK or the European Union, despite the US trade representative Jamieson Greer’s assurances that nothing changes
Novo Nordisk vuelve a hundirse en Bolsa al fallar los ensayos de su nuevo medicamento contra la obesidad
La acción cae más del 16% y se deja ya un 75% desde mediados de 2024. El grupo danés se queda por detrás de su rival estadounidense Eli Lilly Enésimo desplome de Novo Nordisk en Bolsa. Sus acciones s
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out
Novo Nordisk shares have fallen sharply. Their new obesity drug, CagriSema, did not meet expectations in trials. This setback affects future sales and market position. Eli Lilly's shares saw a rise. I
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out
Feb 23 (Reuters) - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-gener
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Novo Nordisk Stock Hits 52-Week Low After Weight-Loss Drug Falls Short Against Eli Lilly's
BenzingaEspañaItalia대한민국日本FrançaisMy AccountBenzinga EdgeBenzinga ResearchBenzinga ProLoginGet Benzinga Pro Data & APIsEventsPremarketAdvertiseContributeEspañaItalia대한민국日本FrançaisLoginRegisterBenzinga
Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly
Take advantage of our newsletter subscription and stay informed on the go!
Novo Nordisk’s obesity drug falls short against Eli Lilly’s in trial
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s tirzepatide in reducing
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa